HK1152474A1 - Methods and compositions for the prevention and treatment of sepsis - Google Patents

Methods and compositions for the prevention and treatment of sepsis

Info

Publication number
HK1152474A1
HK1152474A1 HK11106525.8A HK11106525A HK1152474A1 HK 1152474 A1 HK1152474 A1 HK 1152474A1 HK 11106525 A HK11106525 A HK 11106525A HK 1152474 A1 HK1152474 A1 HK 1152474A1
Authority
HK
Hong Kong
Prior art keywords
sepsis
prevention
compositions
treatment
methods
Prior art date
Application number
HK11106525.8A
Other languages
English (en)
Chinese (zh)
Inventor
Sek Chung Fung
Tom Eirik Mollnes
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1152474A1 publication Critical patent/HK1152474A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK11106525.8A 2003-05-15 2011-06-23 Methods and compositions for the prevention and treatment of sepsis HK1152474A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47068103P 2003-05-15 2003-05-15

Publications (1)

Publication Number Publication Date
HK1152474A1 true HK1152474A1 (en) 2012-03-02

Family

ID=33476736

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11106525.8A HK1152474A1 (en) 2003-05-15 2011-06-23 Methods and compositions for the prevention and treatment of sepsis

Country Status (11)

Country Link
US (1) US8329169B2 (fr)
EP (2) EP2266606B1 (fr)
JP (2) JP4768620B2 (fr)
CN (2) CN1787741B (fr)
AU (2) AU2004241069B2 (fr)
CA (1) CA2524534C (fr)
DK (1) DK1628530T3 (fr)
ES (2) ES2387275T3 (fr)
HK (1) HK1152474A1 (fr)
MX (1) MXPA05011886A (fr)
WO (1) WO2004103294A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001332A2 (fr) * 2004-08-04 2007-01-04 University Of Massachusetts Immunoadhesines anti-pathogene
AU2005313971B2 (en) * 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
CN101932337A (zh) * 2007-06-11 2010-12-29 宾夕法尼亚大学董事会 替代途径的血清灭菌蛋白调节及其应用
WO2009121065A2 (fr) * 2008-03-28 2009-10-01 Apellis Ag Modulation et réplétion/amélioration du système complémentaire dans le traitement des traumatismes
WO2010135717A2 (fr) 2009-05-21 2010-11-25 Potentia Pharmaceuticals, Inc. Dosage de complements et leurs utilisations
CN102597005A (zh) 2009-06-23 2012-07-18 阿雷克森制药公司 与补体蛋白质结合的双特异性抗体
EP2309001A1 (fr) * 2009-09-23 2011-04-13 SIRS-Lab GmbH Procédé de détermination et de différenciation in vitro d'états physiopathologiques
US9358266B2 (en) * 2010-02-25 2016-06-07 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
EP2545075B1 (fr) * 2010-03-10 2020-07-01 NovelMed Therapeutics, Inc. Anticorps anti-properdine humanisés et chimériques
US9011852B2 (en) 2010-04-30 2015-04-21 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies
WO2012145392A2 (fr) * 2011-04-18 2012-10-26 Curators Of The University Of Missouri Conjugués de saccharide
JP5793188B2 (ja) 2011-05-13 2015-10-14 国立大学法人 東京大学 自己免疫疾患治療及び予防薬としてのctrp6
ES2634458T3 (es) * 2011-05-19 2017-09-27 Mochida Pharmaceutical Co., Ltd. Diagnóstico de enfermedad infecciosa del tracto respiratorio usando muestras de sangre
EP2726103B1 (fr) 2011-07-01 2018-09-05 The Trustees Of The University Of Pennsylvania Anticorps anti-properdine et leurs utilisations
CN102533758B (zh) * 2011-10-19 2014-04-02 海南大学 一种抑制水牛膜分化抗原14 基因表达的小核糖核酸分子
CN102363781A (zh) * 2011-10-19 2012-02-29 海南大学 一种有效抑制小鼠mCD14基因表达的小干扰核糖核酸分子
US9051365B2 (en) 2011-12-21 2015-06-09 Novartis Ag Antibodies that bind factor P
JP6538561B2 (ja) * 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体C1s抗体とそれらの用途
CA2889197A1 (fr) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anticorps anti-complement c1s et utilisations de ceux-ci
EP2996722A4 (fr) * 2013-05-15 2017-01-11 Annexon, Inc. Méthodes de traitement du syndrome de guillain-barré
MX2015017341A (es) 2013-07-09 2016-07-06 Anexxon Inc Anticuerpos anti-factor del complemento c1q y uso de los mismos.
CN105683759B (zh) * 2013-08-07 2019-03-29 瑞颂医药公司 非典型溶血性尿毒综合征(aHUS)生物标志物蛋白
WO2015054569A1 (fr) * 2013-10-10 2015-04-16 Viropharma Holdings Limited Procédés d'inhibition de la voie alternative d'activation du système immunitaire complémentaire et compositions utilisées dans ces procédés
WO2015078711A2 (fr) * 2013-11-18 2015-06-04 Westfaelische Wilhelms-Universitaet Muenster Procédés, peptides et anticorps permettant de prévenir, traiter et diagnostiquer une affection inflammatoire
US20170107294A1 (en) * 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
EP3628680B1 (fr) 2014-06-12 2021-09-08 RA Pharmaceuticals, Inc. Modulation d'activité complémentaire
JP6951246B2 (ja) 2014-11-05 2021-10-20 アネクソン,インコーポレーテッド ヒト化抗補体因子C1q抗体及びその使用
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
RS62630B9 (sr) 2015-01-28 2022-04-29 Ra Pharmaceuticals Inc Modulatori aktivnosti komplementa
EP3280440B1 (fr) 2015-04-06 2022-11-16 Bioverativ USA Inc. Anticorps anti-c1s humanisés et leurs procédés d'utilisation
US10975131B2 (en) 2015-10-27 2021-04-13 University Of Massachusetts Factor H-Fc immunotheraphy
SG11201803703UA (en) 2015-11-24 2018-06-28 Annexon Inc Anti-complement factor c1q fab fragments and uses thereof
EP3389692B1 (fr) 2015-12-16 2020-03-04 RA Pharmaceuticals, Inc. Modulateurs de l'activité du complément
WO2017134043A1 (fr) * 2016-02-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et composition pharmaceutique pour la neutralisation de l'activité cytotoxique des protéines histones extracellulaires chez les patient souffrant de sepsie
BR112019011053A2 (pt) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc moduladores da atividade do complemento
WO2019112984A1 (fr) 2017-12-04 2019-06-13 Ra Pharmaceuticals, Inc. Modulateurs de l'activité du complément
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
WO2020011869A2 (fr) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Oligonucléotides antisens ciblant tlr2
CA3131927A1 (fr) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulateurs d'activite du complement
EP3947352A1 (fr) 2019-03-29 2022-02-09 RA Pharmaceuticals, Inc. Modulateurs du complément et procédés associés
CA3137895A1 (fr) 2019-04-24 2020-10-29 Ra Pharmaceuticals, Inc. Compositions et methodes de modulation de l'activite du complement

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP2703764B2 (ja) 1986-04-28 1998-01-26 シータス オンコロジー コーポレイション 補体成分C5aに対するモノクローナル抗体
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
DE69032662T2 (de) 1989-08-01 1999-03-11 Scripps Research Inst Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis
US6315999B1 (en) 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
DE4029227A1 (de) 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
AU2694592A (en) 1991-09-30 1993-05-03 Walser, Mackenzie Methods for treatment of free-radical-mediated tissue injury
WO1993019772A1 (fr) 1992-04-06 1993-10-14 North Shore University Hospital Research Corporation Nouvelle therapie permettant de traiter la septicemie a l'aide d'une forme soluble de l'antigene myelomonocytique cd14 recombine
US6063764A (en) 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US5330754A (en) * 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
DE69431290D1 (de) 1993-02-12 2002-10-10 Avant Immunotherapeutics Inc PULMONÄRE VERABREICHUNG DES LÖSLICHEN KOMPLEMENT-RECEPTORS TYP 1 sCR1
JPH08510909A (ja) 1993-05-28 1996-11-19 ザ スクリップス リサーチ インスティチュート Cd14媒介細胞活性化を抑制するための方法および組成物
AP690A (en) * 1994-07-05 1998-10-16 Steeno Res Group A/S Immunomodulators based on a polypeptide other than human interleukin 10.
DK0792162T3 (da) 1994-09-16 2006-03-27 Scripps Research Inst Anvendelse af antistoffer til blokering af virkningerne af grampositive bakterier og mycobakterier
CN1171117A (zh) * 1994-12-23 1998-01-21 实验室奥姆公司 Mhc-ⅱ结合和/或mhc-ⅱ模拟分子用于预防和/或治疗炎性疾病的用途
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6042821A (en) 1995-11-21 2000-03-28 Smithkline Beecham Corporation Method of treating sepsis with chemokines
US6290948B1 (en) 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
WO1997044054A2 (fr) * 1996-05-22 1997-11-27 University Of Alberta Proteines de fixation de la chimiokine de type 2 et leurs procedes d'utilisation
WO1998017312A1 (fr) 1996-10-22 1998-04-30 Chugai Seiyaku Kabushiki Kaisha Remede contre les troubles septiques et comprenant un anticorps anti-il-8 en qualite d'ingredient actif
US6172220B1 (en) 1997-01-21 2001-01-09 Board Of Regents Of University Of Nebraska Isolated algal lipopolysaccharides and use of same to inhibit endotoxin-initiated sepsis
CA2253877A1 (fr) 1997-03-07 1998-11-09 Mochida Pharmaceutical Co., Ltd. Composes antisens diriges contre cd14
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
ID26730A (id) 1998-05-27 2001-02-01 Gemma Biotechnology Ltd Induksi protein-protein dan peptida-peptida antibiotik oleh lait/scd14-protein
BR9914066A (pt) * 1998-09-24 2002-04-23 Univ Minnesota Polipeptìdio degradador de c3 de complemento humano de streptococcus pneumoniae
WO2000023101A1 (fr) 1998-10-22 2000-04-27 Eli Lilly And Company Methodes de traitement de la septicemie
US20030114377A1 (en) 1998-11-18 2003-06-19 Kirkland Theo N. Inhibition therapy for septic shock with mutant CD14
DE19913707A1 (de) 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunadsorber zur Sepsistherapie
TR200102913T2 (tr) * 1999-04-09 2002-01-21 Basf Aktiengesellschaft Tam proteazların düşük moleküler ağırlıklı inhibitörleri.
CA2373942A1 (fr) * 1999-05-18 2000-11-23 Teijin Limited Remedes ou prophylactase contre les maladies associees a des chimiokines
US6673346B1 (en) * 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
JP2003522159A (ja) * 2000-02-08 2003-07-22 ザ ユニバーシティ オブ ヴァージニア パテント ファウンデーション 抗C3b(i)抗体を用いる感染の予防および治療のための方法
US20020006915A1 (en) 2000-02-15 2002-01-17 Mack Strong Vivian E. Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation
US20040092712A1 (en) 2000-03-31 2004-05-13 Shoji Furusako Tlr/cd14 binding inhibitor
EP1275713A4 (fr) * 2000-03-31 2004-06-30 Mochida Pharm Co Ltd Inhibiteur de liaison entre le recepteur de type toll et cd14
IL154993A0 (en) 2000-09-29 2003-10-31 Neurogen Corp High affinity small molecule c5a receptor modulators
US7264967B2 (en) 2000-11-22 2007-09-04 Mochida Pharmaceutical Co., Ltd. Anti-CD14 monoclonal antibody having effect of inhibiting CD14/TLR binding
WO2002072636A2 (fr) 2000-12-28 2002-09-19 Altus Biologics Inc. Cristaux d'anticorps entiers et fragments d'anticorps et methodes de fabrication et d'utilisation associees
WO2002074789A2 (fr) * 2001-03-20 2002-09-26 Baylor College Of Medicine Utilisation d'anticorps monoclonaux et essais fonctionnels pour la prevision d'un risque d'infection opportuniste
ES2334773T3 (es) 2001-05-16 2010-03-16 Yeda Research And Development Co. Ltd. Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis.
US7432356B2 (en) * 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
EP1601377A4 (fr) * 2003-02-21 2009-07-15 Genentech Inc Procedes de traitement et de prevention des lesions tissulaires associees aux blessures par reperfusion ischemique

Also Published As

Publication number Publication date
CN1787741B (zh) 2011-08-17
AU2010249190A1 (en) 2011-01-06
ES2522525T3 (es) 2014-11-14
ES2387275T3 (es) 2012-09-19
CA2524534C (fr) 2012-12-11
EP1628530B1 (fr) 2012-06-06
AU2004241069A1 (en) 2004-12-02
EP1628530B8 (fr) 2012-08-01
DK1628530T3 (da) 2012-07-23
CA2524534A1 (fr) 2004-12-02
EP1628530A4 (fr) 2007-08-29
US20070274989A1 (en) 2007-11-29
JP4768620B2 (ja) 2011-09-07
JP2011105747A (ja) 2011-06-02
EP1628530A2 (fr) 2006-03-01
EP2266606B1 (fr) 2014-09-10
AU2010249190B2 (en) 2013-02-28
JP2006528981A (ja) 2006-12-28
EP2266606A1 (fr) 2010-12-29
CN102258784A (zh) 2011-11-30
MXPA05011886A (es) 2006-02-17
AU2004241069B2 (en) 2010-09-09
WO2004103294A2 (fr) 2004-12-02
WO2004103294A3 (fr) 2005-05-26
CN1787741A (zh) 2006-06-14
US8329169B2 (en) 2012-12-11

Similar Documents

Publication Publication Date Title
HK1152474A1 (en) Methods and compositions for the prevention and treatment of sepsis
PT1644021E (pt) Métodos e composições para o tratamento de distúrbios gastrointestinais
ZA200704677B (en) Compositions and methods for the treatment of autism
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
EP1633718A4 (fr) Compositions et procedes d'inhibition du facteur de croissance transformant beta (tgf-$g(b))
EP1692085A4 (fr) Inhibition de recepteur fgfr3 et traitement de myelome multiple
EP1711197A4 (fr) Methodes et compositions pour la prevention et le traitement de maladies ou de troubles inflammatoires
AU2003290605A8 (en) Compositions and methods for the diagnosis and treatment of sepsis
IL174627A0 (en) Compositions and methods for treatment of burns
IL183709A0 (en) Compositions and methods for treating conditions of the nail unit
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
EP1537089A4 (fr) Composes, compositions et procedes
EP1720563A4 (fr) Procedes et compositions de traitement de l'inflammation
IL187405A0 (en) Methods and compositions for the treatment of pain
EP1651255A4 (fr) Compositions veterinaires topiques et methodes de traitement et de prevention d'infections
AU2003297573A8 (en) Compositions and methods for treating transplants
IL165839A0 (en) Compounds useful for the treatment of cancer compositions thereof and methods therewith
EP1670492A4 (fr) Cytokines de protection des tissus pour le traitement et la prevention des septicemies et de la formation d'adhesions
SI1812797T1 (sl) Pripravki in metode zdravljenja ter preprečevanja hiperprolifetarivnih bolezni
PL368035A1 (en) Compositions and methods for the treatment of cancer
GB0324523D0 (en) Compositions and methods of treatment
EP1755581A4 (fr) Methodes et compositions de traitement d'etats myocardiques
AU2003220026A1 (en) Methods and compositions for the treatment of ischemia
AU2002303552A8 (en) Methods and compositions for prevention of angioproliferation
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200518